Dr. Weihong Song, researcher with the Brain Research Centre at Vancouver Coastal Health and UBC has identified the molecule that controls a scissor-like protein responsible for the production of plaques in the brain – a telltale sign of Alzheimer’s disease (AD).
The molecule, known as GSK3-beta, activates a series of events resulting in amyloid beta production; these molecular fragments form tiny fibers that clump together into plaques, eventually killing neural cells.
Previous research has shown that GSK3-beta also spurs the growth of twisted fibers inside neurons, known as tangles, which are another hallmark of AD. This one protein is therefore now identified as playing a role in two key links to the disease. This discovery by Dr. Song will mean heightened interest in pursuing this protein as a dual target for drug therapies.
In his research, Dr. Song, who is also the Canada Research Chair in Alzheimer’s disease and professor of psychiatry at UBC, found that disabling GSK3-beta’s effect in mice resulted in far fewer deposits of amyloid in their brains. His study also found that mice who’s GSK3-beta was blocked performed better than untreated mice on memory tests.
While this discovery is very exciting to Alzheimer’s disease researchers, it is important to note that even though GSK3-beta plays a destructive role in AD, it is also a versatile enzyme that controls many vital functions in the body. As a result, inhibiting the molecule could cause several serious side effects, including cancer.
In order to develop a targeted AD treatment, more research is required into the specific molecular mechanisms of GSK3-beta to specifically knock out only the deadly functions.
Dr. Song’s work was published in the Journal of Clinical Investigation on December 3, 2012. For a full version of the media release click here.